IE 11 is not supported. For an optimal experience visit our site on another browser.

China Nuokang Bio-Pharmaceutical Inc. to Report First Quarter 2011 Financial Results

/ Source: GlobeNewswire

BEIJING, May 12, 2011 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today provided updated dial-in details for its first quarter 2011 conference call, to be held at 8:00 am ET on Thursday, May 26, 2011. The first quarter 2011 financial results will be released on Wednesday, May 25, 2011 after the market closes.

Listeners may access the call by dialing:

A telephone replay will be available beginning two hours after the conclusion of the call and will be available through June 8, 2011. Listeners may access the replay by dialing:

A webcast will also be available through the Company's website www.nkbp.com.

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 2,400 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, and Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information.

CONTACT: ICR, LLC In the U.S.: Ashley De Simone: 1-646-277-1227 In China: Wen Lei Zheng: 86-10-6583-7510